Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM32FKD)

• Drug Name: PF-228 Drug Info
• Synonyms: 869288-64-2; PF-573228; PF 573228; PF573228; PF-228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 11612883
  ChEBI ID: CHEBI:91446
  CAS Number: CAS 869288-64-2
  TTD Drug ID: DM32FKD

Molecule-Related Drug Atlas

Drug(s) Targeting Focal adhesion kinase 1 (FAK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VS-6063	DMGBLI3	Mesothelioma	2C51.2	Phase 2	[3]
BI-853520	DMNOSYW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
PF-562271	DMSLE03	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
VS-4718	DMN9JCD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
GSK-2256098	DMR24MI	Pulmonary arterial hypertension	BB01.0	Phase 1	[7]
CEP-37440	DMV632P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
IN10018	DMPXOVA	Metastatic melanoma	2E2Z	Phase 1	[8]
1,2,4-triazolo[1,5a]pyridine derivative 1	DMIUPSA	N. A.	N. A.	Patented	[9]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[10]
PMID23414845C30	DMNVQ29	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting Cyclin-dependent kinase 1 (CDK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[12]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[12]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[14]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[15]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[17]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[18]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[19]

Drug(s) Targeting Cyclin-dependent kinase 7 (CDK7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[12]
Samuraciclib	DM54FQA	Breast cancer	2C60-2C65	Phase 1/2	[20]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[21]
BTX-A51	DMC8XHQ	Advanced solid tumour	2A00-2F9Z	Phase 1	[22]
SY-1365	DMK48PM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[23]
LY3405105	DMB51K2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[24]
SY-5609	DMNW3LH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[25]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[17]
Roscovitine derivative 1	DMD1G3Z	N. A.	N. A.	Patented	[17]
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[17]

Drug(s) Targeting Cyclin-dependent kinase 2 (CDK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[12]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
PHA848125	DMS2Q9G	Thymic cancer	2C27	Phase 2	[26]
TG02	DMZFIGQ	Anaplastic astrocytoma	2A00.0	Phase 1/2	[27]
NUV-422	DMQJQNT	Malignant glioma	2A00.0	Phase 1/2	[28]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[15]
FN-1501	DM7BMD6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[29]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[21]

Drug(s) Targeting Glycogen synthase kinase-3 beta (GSK-3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMO-02	DMJRU3A	Myotonic dystrophy	8C71.0	Phase 2/3	[30]
LY2090314	DMTBFE4	Acute myeloid leukaemia	2A60	Phase 2	[31]
Lithium	DMZ3OU6	Bipolar disorder	6A60	Phase 2	[32]
Tideglusib	DME4LA1	Alzheimer disease	8A20	Phase 2	[33]
9-ING-41	DM57TY3	Myelofibrosis	2A20.2	Phase 2	[34]
Neu-120	DMXKOUC	Parkinson disease	8A00.0	Phase 1/2	[35]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[36]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[37]
TDZD-8	DMG6Q45	Malignant glioma	2A00.0	Patented	[38]
AR-A014418	DMUPN01	Ovarian cancer	2C73	Patented	[39]

Drug(s) Targeting Inhibitor of nuclear factor kappa-B kinase beta (IKKB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Parthenolide	DMCQBFT	N. A.	N. A.	Phase 2	[41]
SAR-113945	DMMCA9V	Osteoarthritis	FA00-FA05	Phase 2	[42]
IMD-1041	DMU1MR9	Alzheimer disease	8A20	Phase 2	[43]
IMD-0354	DMOFSLE	Acne vulgaris	ED80	Phase 1	[44]
MLN0415	DMG72VK	Arthritis	FA20	Discontinued in Phase 1	[45]
5-Bromo-6-methoxy-9H-beta-carboline	DM157OQ	Discovery agent	N.A.	Investigative	[46]
Staurosporine	DM0E9BR	Discovery agent	N.A.	Investigative	[47]
5-amino-2-phenyl-oxazole-4-carboxylic acid amide	DMX37ZC	Discovery agent	N.A.	Investigative	[48]
5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide	DM4SWJ7	Discovery agent	N.A.	Investigative	[48]

Drug(s) Affected By Focal adhesion kinase 1 (PTK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[49]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[50]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[51]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[53]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[54]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[55]
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[56]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin-dependent kinase 1 (CDK1)	TTH6V3D	CDK1_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 2 (CDK2)	TT7HF4W	CDK2_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 7 (CDK7)	TTQYF7G	CDK7_HUMAN	Inhibitor	[1]
Focal adhesion kinase 1 (FAK)	TTON5IT	FAK1_HUMAN	Inhibitor	[1]
Glycogen synthase kinase-3 beta (GSK-3B)	TTRSMW9	GSK3B_HUMAN	Inhibitor	[1]
Inhibitor of nuclear factor kappa-B kinase beta (IKKB)	TTJ3E9X	IKKB_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Focal adhesion kinase 1 (PTK2)	OT3Q1JDY	FAK1_HUMAN	Post-Translational Modifications	[2]

References

• [1] Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
• [2] Aryl hydrocarbon receptor-dependent up-regulation of the heterodimeric amino acid transporter LAT1 (SLC7A5)/CD98hc (SLC3A2) by diesel exhaust particle extract in human bronchial epithelial cells. Toxicol Appl Pharmacol. 2016 Jan 1;290:74-85.
• [3] Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.
• [4] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [5] Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011 Nov;10(11):2135-45.
• [6] FAK Inhibition disrupts a beta5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth. Mol Cancer Ther. 2014 Aug;13(8):2050-61.
• [7] A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13(19):3143-9.
• [8] Clinical pipeline report, company report or official report of InxMed.
• [9] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
• [10] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [11] Structure-based discovery of cellular-active allosteric inhibitors of FAK. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1779-85.
• [12] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [13] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [14] P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
• [15] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [16] A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
• [17] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [18] c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
• [19] Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
• [20] The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer. 2023 Jun;128(12):2326-2337.
• [21] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [22] Clinical pipeline report, company report or official report of BioTheryX.
• [23] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [24] CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823.
• [25] Clinical pipeline report, company report or official report of Syros Pharmaceuticals.
• [26] Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
• [27] Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
• [28] ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
• [29] Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
• [30] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [31] Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
• [32] The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
• [33] Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
• [34] 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
• [35] Company report (Neurim Pharmaceuticals)
• [36] 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
• [37] Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
• [38] Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
• [39] Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
• [40] How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002 Sep;2(9):705-13.
• [41] The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001 Aug;8(8):759-66.
• [42] The NF B pathway: a therapeutic target in glioblastoma. Oncotarget. 2011 August; 2(8): 646-653.
• [43] Inhibition of I B phosphorylation prevents load-induced cardiac dysfunction in mice. Am J Physiol Heart Circ Physiol. 2012 Dec 15;303(12):H1435-45.
• [44] I B kinase beta inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Clin Exp Allergy. 2011 Jan;41(1):104-15.
• [45] Company report (Millennium)
• [46] Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22.
• [47] UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996 Jul 17;88(14):956-65.
• [48] Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
• [49] Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
• [50] Cleavage of focal adhesion kinase is an early marker and modulator of oxidative stress-induced apoptosis. Chem Biol Interact. 2008 Jan 10;171(1):57-66. doi: 10.1016/j.cbi.2007.08.009. Epub 2007 Aug 19.
• [51] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [52] Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-B and matrix metalloproteinase-2/-9 signaling pathways. Anticancer Res. 2013 May;33(5):1941-50.
• [53] Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
• [54] Activation of cannabinoid receptors promote periodontal cell adhesion and migration. J Clin Periodontol. 2019 Dec;46(12):1264-1272. doi: 10.1111/jcpe.13190. Epub 2019 Oct 22.
• [55] Monomeric and oligomeric flavanols are agonists of membrane androgen receptors. Exp Cell Res. 2005 Oct 1;309(2):329-39. doi: 10.1016/j.yexcr.2005.06.011.
• [56] Disruption of FAK signaling: a side mechanism in cytotoxicity. Toxicology. 2008 Mar 12;245(1-2):1-10. doi: 10.1016/j.tox.2007.12.003. Epub 2007 Dec 15.
• [57] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [58] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.